Does anyone know where I can source Cortexin?

I notice nothing from using it.

Thoughts on loading syringes for the week instead of going 10 unit draw every day load ten days and reuse - cleaning everytime of course ? ???

@Derek Pruski Any recommendations for 0.9% sodium chloride in water sourcing? I checked your Amazon store and didn't see any?

Neuropathy is a condition where nerves become damaged or irritated, leading to symptoms such as pain, tingling, numbness, or weakness. Many people around the world suffer from different types of neuropathy—sometimes as a result of diabetes, autoimmune conditions, infections, or other injuries to the nerves. Scientists and healthcare professionals are always looking for new ways to help repair nerves and relieve these symptoms. One area of exciting research involves a compound called ARA‑290. What Is ARA‑290? ARA‑290 is a small, lab-made peptide (a short chain of amino acids). It was developed based on an important part of a naturally occurring protein called erythropoietin (EPO). Normally, EPO is famous for helping the body make red blood cells, but researchers discovered that a small segment of this molecule can also help protect tissues and reduce inflammation without affecting blood cell production. How Might ARA‑290 Help with Neuropathy? 1. Targeting Inflammation and Nerve Damage: In many forms of neuropathy, inflammation (the body's natural response to injury) can worsen nerve damage. ARA‑290 is thought to bind to specific receptors known as innate repair receptors on damaged tissues. This interaction might help calm down inflammation and encourage the repair of nerves. 2. Improving Nerve Function: By reducing the inflammation and encouraging nerve healing, ARA‑290 could help decrease pain and improve nerve function. This means that it might lessen the burning, tingling, or numb sensations that people with neuropathy experience. 3. Tissue Protection:The molecule has been designed to protect tissues from further damage. This is especially important in chronic conditions where ongoing nerve damage can lead to long-term disability. What Do We Know So Far? - Research Phase: Most of the work done on ARA‑290 so far has been in the research and clinical trial phases. Early studies have provided encouraging results regarding its ability to reduce symptoms of neuropathic pain in certain conditions like sarcoidosis (an inflammatory disease) and possibly diabetic neuropathy. - Safety and Efficacy: Because ARA‑290 is derived from part of the EPO molecule but without affecting red blood cell production, researchers hope it will provide benefits without some of the risks associated with full EPO therapy. However, like any new treatment, it must be tested rigorously to ensure it is both safe and effective for widespread use.